The latter category targets the tumor-associated antigens, such as MUC1, survivin, as well as CEA and signal transducer and activator of transcription 3 (STAT3); however, their application in CRC patients did not significantly increase their survival. The gene discussed is CEACAM5; the disease is neoplasm.